Cancer Immunology, Immunotherapy : Impact Factor & More
eISSN: 1432-0851pISSN: 0340-7004
Share this on:
Key Metrics
CiteScore 
10
Impact Factor
5 - 10
SNIP
1.25
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Cancer Immunology, Immunotherapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1976 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cancer Immunology, Immunotherapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Immunology, Immunotherapy
Cytokine-induced killer (CIK) Cells-associated transcriptome signature reveals the potential immunomodulatory role of TNFSF14 in clear cell renal cell carcinoma.
- 20 May 2026
- Cancer immunology, immunotherapy : CII
Decoding circulating neutrophil phenotypes in triple-negative breast cancer via optimized single-cell RNA sequencing.
- 19 May 2026
- Cancer immunology, immunotherapy : CII
Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition.
- 19 May 2026
- Cancer immunology, immunotherapy : CII
Early increase of CD103 expression on peripheral PD-1+ CD8+ T cells predicts response to nivolumab in advanced esophageal squamous cell carcinoma.
- 19 May 2026
- Cancer immunology, immunotherapy : CII
Correction: Metabolic syndrome and immune-related adverse events
- 14 May 2026
- Cancer Immunology, Immunotherapy : CII
Seasonal variation in immune-related adverse events in advanced cancer patients.
- 12 May 2026
- Cancer immunology, immunotherapy : CII
Cytokine-induced killer (CIK) Cells-associated transcriptome signature reveals the potential immunomodulatory role of TNFSF14 in clear cell renal cell carcinoma.
- 20 May 2026
- Cancer immunology, immunotherapy : CII
Decoding circulating neutrophil phenotypes in triple-negative breast cancer via optimized single-cell RNA sequencing.
- 19 May 2026
- Cancer immunology, immunotherapy : CII
Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition.
- 19 May 2026
- Cancer immunology, immunotherapy : CII
Early increase of CD103 expression on peripheral PD-1+ CD8+ T cells predicts response to nivolumab in advanced esophageal squamous cell carcinoma.
- 19 May 2026
- Cancer immunology, immunotherapy : CII
Correction: Metabolic syndrome and immune-related adverse events
- 14 May 2026
- Cancer Immunology, Immunotherapy : CII
Seasonal variation in immune-related adverse events in advanced cancer patients.
- 12 May 2026
- Cancer immunology, immunotherapy : CII
FAQs on Cancer Immunology, Immunotherapy
How long has Cancer Immunology, Immunotherapy been actively publishing? 
What is the publishing frequency of Cancer Immunology, Immunotherapy?
How many articles did Cancer Immunology, Immunotherapy publish last year?
What is the eISSN & pISSN for Cancer Immunology, Immunotherapy?
What is Citescore for Cancer Immunology, Immunotherapy?
What is SNIP score for Cancer Immunology, Immunotherapy?
Who is the publisher of Cancer Immunology, Immunotherapy?
